Table 4.
Overall performance of rounds 2 and 3 participants using top five commercial kits or platforms in SARS-CoV-2 proficiency testing program
| Round | Assay | Concordant (%) |
Discordant (%) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| S6 | S7 | S8 | S9 | S10 | S6 | S7 | S8 | S9 | S10 | ||
| 2 (May 2020) | Cepheid GeneXpert Xpert Xpress SARS-CoV-2 | 97.8 | 100 | 91.5 | 97.8 | 100 | 2.2 | – | 8.5 | 2.2 | – |
| Seegene Allplex 2019-nCoV | 100 | 100 | 69.2 | 92.9 | 100 | – | – | 30.8 | 7.1 | – | |
| AusDiagnostics SARS-CoV-2, Influenza and RSV (8-Well) | 100 | 100 | 100 | 100 | 100 | – | – | – | – | – | |
| Roche Diagnostics Cobas SARS-CoV-2 | 100 | 100 | 81.8 | 100 | 100 | 18.2 | – | – | |||
| Hologic Panther Fusion SARS-CoV-2 assay | 100 | 100 | NA | 100 | 100 | – | – | NA | – | – | |
| 3 (Nov 2020) | S11 | S12 | S13 | S14 | S15 | S11 | S12 | S13 | S14 | S15 | |
| Cepheid GeneXpert Xpert Xpress SARS-CoV-2 | 100 | 100 | 100 | 94.0 | 94.0 | – | – | – | 6.0 | 6.0 | |
| Seegene Allplex 2019-nCoV | 100 | 100 | 100 | 100 | 100 | – | – | – | – | – | |
| Roche Diagnostics Cobas SARS-CoV-2 | 100 | 100 | 100 | 100 | 100 | – | – | – | – | – | |
| AusDiagnostics SARS-CoV-2, Influenza and RSV (8-Well) | 100 | 100 | 100 | 100 | 100 | – | – | – | – | – | |
| Seegene Allplex SARS-CoV-2 assay | 100 | 100 | 100 | 100 | 100 | ||||||
NA, results not assessed; S6, SARS-CoV-2 positive; S7, SARS-CoV-2 positive; S8, SARS-CoV-2 presumptive positive (inconclusive); S9, SARS-CoV-2 negative; S10, SARS-CoV-2 positive; S11, SARS-CoV-2 negative; S12, SARS-CoV-2 negative; S13, SARS-CoV-2 negative; S14, SARS-CoV-2 positive; S15, SARS-CoV-2 positive.